Glucotrack (Nasdaq:GCK) announced today that it completed a feasibility study for its implantable continuous glucose monitor (CGM). Rutherford, New Jersey-based Glucotrack designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes. The company said late last year that it planned to expand its product pipeline with an R&D program. The program centers around developing […]
Clinical Trials
Better Therapeutics wins FDA nod for type 2 diabetes digital therapeutic
Better Therapeutics (Nasdaq:BTTX) announced that the FDA authorized its AspyreRx prescription digital therapeutic for diabetes. AspyreRx, formerly BT-001, provides cognitive behavioral therapy to patients 18 years or older with type 2 diabetes. The prescription-only digital therapeutic (PDT) underwent review through the FDA de novo pathway. The company submitted an FDA de novo request in September 2022 for […]
Study supports use of CamDiab artificial pancreas in pregnant women with type 1 diabetes
The CamDiab CamAPS FX automated insulin delivery (AID) system produced better outcomes for pregnant women with type 1 diabetes in a clinical study. Medscape reported that data came from the largest randomized controlled trial pitting an AID system against standard insulin delivery in pregnant women with type 1 diabetes. The automated CamAPS FX came out […]
The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions
As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space. At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for […]
Study shows health equity impact from Virta Health diabetes reversal platform
Virta Health announced that real-world data for its diabetes reversal platform demonstrated narrowing gaps in care. The company shared its data at the American Diabetes Association’s 83rd Scientific Sessions. The research highlighted its impact on health equity. It demonstrated significant health improvement and medication reduction for members in the most and least disadvantaged U.S. neighborhoods. […]
Vida Health reports positive data for virtual diabetes program in low-income populations
Vida Health announced new research demonstrating significantly lowered A1C levels with its virtual cardiometabolic program. The research highlighted use of the program in low-income Medicare Advantage members. Significantly lowered A1C levels even occurred in areas with limited income and food access. Vida Health’s study compared its members living in areas of low income and low […]
Sernova reports positive interim data for Cell Pouch System
Sernova today announced positive interim data from the clinical trial of its Cell Pouch System in patients with type 1 diabetes. London, Ontario-based Sernova designed its proprietary Cell Pouch System as an implantable and scalable medical device. It forms a natural environment in the body for the long-term survival and function of therapeutic cells. Those […]
Studies back Fractyl Health diabetes reversal procedure, gene therapy
Fractyl Health announced multiple studies supporting its programs for the reversal and treatment of diabetes. Lexington, Massachusetts-based Fractyl reported data from its Revitalize 1 pivotal study and its Rejuva program. Revitalize 1 evaluates the company’s Revita endoscopic ablation procedure to reverse diabetes. Rejuva evaluates a targeted pancreatic gene therapy. The company presented its results at […]
Data supports safety and accuracy of Senseonics 365-day CGM
Senseonics (NYSE:SENS) today announced positive clinical data highlighting the effectiveness of its Eversense continuous glucose monitor (CGM). Germantown, Maryland-based Senseonics presented two studies on its latest-generation Eversense E3 at the American Diabetes Association 83rd Scientific Session. The 180-day implantable CGM received FDA approval in February of last year. The sensor is fully implantable and requires just […]
Once-weekly insulin from Novo Nordisk meets clinical trial endpoints
Novo Nordisk announced data that met primary endpoints from clinical trials investigating its once-weekly basal insulin icodec. While meeting primary endpoints, the studies also demonstrated reduced injections. These injections decreased from seven to one per week with once-daily basal insulin. Novo Nordisk presented results at the 83rd Annual Scientific Sessions of the American Diabetes Association […]
